Pharmafile Logo
Pharmafocus logo
Advanced Search

AbbVie

Showing 15 posts of 222 posts found.

gary_gordon

Ayala hires AbbVie’s Gary Gordon as new CMO

September 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Ayala

AbbVie’s former Vice President of Oncology has moved to Ayala Pharmaceuticals to work as its new Chief Medical Officer (CMO).  …

Appointment
abbvie_0

AbbVie shuts down Rova-T development in first-line advanced small-cell lung cancer following another trial failure

August 30, 2019
Medical Communications, Research and Development AbbVie, pharma, rova-t, small-cell lung cancer

AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung …

News
5204602349_c87b204860_z

FDA warns three Hepatitis C drugs may worsen liver function in some rare cases

August 29, 2019
Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health

The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …

News

NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation

August 21, 2019
Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …

News
abbvie_0

AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis

August 19, 2019
Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis

The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …

News
humira_abbott__4

Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US

July 24, 2019
Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma

It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 28, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit

This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …

News
shutterstock_273326141

AbbVie poised to acquire Allergan for $63 billion

June 26, 2019
Research and Development, Sales and Marketing AbbVie, Allergan, acqusition, pharma

The industry has been rocked with the announcement of another pharmaceutical mega-merger, as it emerged that AbbVie had sealed an …

News
abbvie_0

AbbVie’s Venclyxto combo outclasses chemo in treatment-naive chronic lymphocytic leukaemia

June 5, 2019
Research and Development ASCO 2019, AbbVie, Venclyxto, pharma

AbbVie was one of many companies to present new data at this year’s American Society of Clinical Oncology (ASCO) Annual …

News
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019
Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …

News

FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia

May 16, 2019
Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma

Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …

News

FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)

May 1, 2019
Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma

The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …

News
abbvie_0

AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis

April 24, 2019
Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis

AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …

News
abbvie_0

Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications

March 27, 2019
Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …

News
roche_dark_0

FDA puts multiple myeloma trial on hold after patient deaths

March 20, 2019
Research and Development AbbVie, FDA, Roche, clinical trials, multiple myeloma

The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023